Department of Pediatrics, National Defense Medical College, Tokorozawa, Japan.
Circ J. 2012;76(6):1501-8. doi: 10.1253/circj.cj-11-1281. Epub 2012 Feb 25.
Mutations in the bone morphogenetic protein receptor type 2 (BMPR2) gene, the activin receptor-like kinase 1 (ALK1) gene, and SMAD8 gene have been reported in heritable pulmonary arterial hypertension (HPAH) and in idiopathic pulmonary arterial hypertension (IPAH). However, almost 30% of HPAH cases and 60-90% of IPAH cases have no mutations in those genes. This suggests that there remain unidentified genes associated with HPAH and IPAH.
This study screened for mutations in endoglin, SMAD1, SMAD2, SMAD3, SMAD4, SMAD5, SMAD6, SMAD7, bone morphogenetic protein receptor type 1A (BMPR1A) and bone morphogenetic protein receptor type 1B (BMPR1B) genes in 43 IPAH patients who had no mutations in BMPR2, ALK1 and SMAD8. Two missense mutations (c.479 G>A S160N, c.1176 C>A F392L) in BMPR1B were each identified in 2 IPAH patients. Immunoblot analysis revealed that the BMPR1B F392L protein promoted SMAD8 phosphorylation. The response to BMP was analyzed using promoter-reporter activities. The transcriptional activation of the BMPR1B F392L protein with SMAD8 increased above that of wild-type BMPR1B with SMAD8, and those of BMPR1B S160N and F392L with SMAD8 and SMAD4 were each increased above those of the wild-type BMPR1B with SMAD8 and SMAD4.
We identified 2 novel mutations in BMPR1B in 2 patients with IPAH. Our study suggests that BMPR1B mutations are associated with the pathogenesis of IPAH.
骨形成蛋白受体 2 型(BMPR2)基因、激活素受体样激酶 1(ALK1)基因和 SMAD8 基因突变已在遗传性肺动脉高压(HPAH)和特发性肺动脉高压(IPAH)中报道。然而,近 30%的 HPAH 病例和 60-90%的 IPAH 病例中没有这些基因的突变。这表明仍然存在与 HPAH 和 IPAH 相关的未识别基因。
本研究在 43 名 IPAH 患者中筛选了内皮素、SMAD1、SMAD2、SMAD3、SMAD4、SMAD5、SMAD6、SMAD7、骨形成蛋白受体 1A(BMPR1A)和骨形成蛋白受体 1B(BMPR1B)基因的突变,这些患者在 BMPR2、ALK1 和 SMAD8 中均无突变。在 2 名 IPAH 患者中分别发现了 BMPR1B 中的 2 个错义突变(c.479 G>A S160N,c.1176 C>A F392L)。免疫印迹分析显示,BMPR1B F392L 蛋白促进了 SMAD8 的磷酸化。使用启动子报告基因活性分析了 BMP 的反应。BMPR1B F392L 蛋白与 SMAD8 的转录激活高于野生型 BMPR1B 与 SMAD8 的转录激活,BMPR1B S160N 和 F392L 蛋白与 SMAD8 和 SMAD4 的转录激活均高于野生型 BMPR1B 与 SMAD8 和 SMAD4 的转录激活。
我们在 2 名 IPAH 患者中鉴定了 BMPR1B 的 2 个新突变。我们的研究表明,BMPR1B 突变与 IPAH 的发病机制有关。